

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

**Claims 1. – 18. (Canceled)**

**Claim 19. (Currently amended)** A method for diagnosis or therapy of tumours or a vascular proliferation disease in a patient ~~comprises~~ comprising administering an antibody with specific, high affinity for the ED-B domain of fibronectin having a VH domain with the following amino acid sequence:

VH domain (SEQ ID NO: [[30]]**19**)

EVQLLESGGG	LVQPGGSLRL	SCAASGFTFS
SFSMSWVRQA	PGKGLEWVSS	ISGSSGTTY
ADSVKGRFTI	SRDNSKNTLY	LQMNSLRAED
TA VYYCAKPF	PYFDYWGQGTLVTVSS	

and having a VL domain with the amino acid sequence encoded by the VL domain encoding DNA of the DNA insert of ATCC deposit no. PTA-9529.

**Claim 20. (Currently amended)** A conjugate comprising (a) an antibody with specific, high affinity for the ED-B domain of fibronectin having a VH domain with the following amino acid sequence:

VH domain (SEQ ID NO: [[30]]**19**)

EVQLLESGGG	LVQPGGSLRL	SCAASGFTFS
SFSMSWVRQA	PGKGLEWVSS	ISGSSGTTY
ADSVKGRFTI	SRDNSKNTLY	LQMNSLRAED
TA VYYCAKPF	PYFDYWGQGTLVTVSS	

and having a VL domain with the amino acid sequence encoded by the VL domain

encoding DNA of the DNA insert of ATCC deposit no. PTA-9529; and (b) a molecule capable of inducing blood coagulation and blood vessel occlusion.

**Claim 21. (Previously presented)** A conjugate according to claim 20 wherein the molecule capable of inducing blood coagulation and blood vessel occlusion is a photoactive molecule.

**Claim 22. (Previously presented)** A conjugate according to claim 21 wherein the photoactive molecule is a photosensitizer.

**Claim 23. (Previously presented)** A conjugate according to claim 22 wherein the photosensitizer absorbs at a wavelength above 600 nm.

**Claim 24. (Currently Amended)** A conjugate according to claim 22 wherein the ~~photosensitizer~~ photosensitizer is a derivative of tin (IV) chlorine e6.

**Claim 25. (Previously Presented)** A conjugate according to claim 20 wherein the molecule capable of inducing blood coagulation and blood vessel occlusion is a radionuclide.

**Claim 26. (Previously Presented)** A conjugate according to claim 25 wherein the radionuclide is a  $\beta$ - emitting radionuclide.

**Claim 27. (Cancelled)**

**Claim 28. (Previously Presented)** A conjugate according to claim 20 comprising a molecule capable of inducing blood coagulation and blood vessel occlusion which is a photosensitizer and a molecule which is a radionuclide.

**Claim 29. (Previously Presented)** A method for the treatment of an angiogenesis-related pathology in a patient comprising administering a conjugate according to claim 20.

**Claim 30. (Previously Presented)** A method for the treatment of an angiogenesis-related

pathology in a patient comprising administering a conjugate according to claim 22 by injections, followed by irradiating said patient.

**Claim 31. (Previously Presented)** A method according to claim 30 wherein the angiogenesis-related pathology treated is caused by or associated with ocular angiogenesis.

**Claim 32. (Previously Presented)** A method for the treatment of an angiogenesis-related pathology comprising administering a radionuclide-containing conjugate according to claim 25 by injection.

**Claim 33. (Previously Presented)** A method according to claim 32 wherein the radionuclide is astatine-211.

**Claim 34. (Previously Presented)** A method for the treatment of an angiogenesis-related pathology comprising administering a conjugate according to claim 28 by injection.

**Claim 35. (Cancelled)**

**Claim 36. (Previously Presented)** A conjugate of claim 20 wherein the antibody further comprises a linking sequence with the amino acid sequence encoded by the linker-encoding DNA of the DNA insert of ATCC deposited no. PTA-9529.

**Claim 37. (Previously Presented)** A conjugate of claim 36 wherein the antibody is radiolabeled.

**Claim 38. (Previously Presented)** A conjugate of claim 37 wherein the antibody is radioiodinated.

**Claim 39. (Previously Presented)** A conjugate of claim 36 wherein the antibody is an ScFv antibody.

**Claim 40. (Previously Presented)** A conjugate of claim 39 wherein the antibody is produced recombinantly.

**Claim 41. (Previously Presented)** A conjugate of claim 36 wherein the ED-B domain of fibronectin is a human ED-B domain.

**Claim 42. (Previously Presented)** A conjugate of claim 36 wherein the antibody is monoclonal.

**Claim 43. (Previously Presented)** A diagnostic kit comprising a conjugate of claim 37 and one or more reagents for detecting angiogenesis.

**Claim 44. (Previously Presented)** A conjugate comprising (a) an scFv antibody with specific, high affinity for the ED-B domain of fibronectin having VH, VL and linker domains with the amino acid sequences encoded, respectively, by the VH-, VL- and linker-DNA of the DNA insert of ATCC deposit no. PTA-9529 and (b) a molecule capable of inducing blood coagulation and blood vessel occlusion.

**Claim 45. (Currently Amended)** A conjugate comprising (a) an antibody with specific, high affinity for the ED-B domain of fibronectin and having a VH domain linked to a VL domain, wherein said VH domain has the following amino acid sequence:

VH domain (SEQ ID NO: [[30]]**19**)

EVQLLES	GGG	LVQPGG	SLRL	SCAASG	FTFS
SFSMSW	VRQA	PGKGLE	WVSS	ISGSSG	TTY
ADSVKGR	FTI	SRDNSK	NTRY	LQMNSL	RAED
TAVYYC	AKPF	PYFDY	WGQG	TLVTV	SS,

and (b) a molecule capable of inducing blood coagulation and blood vessel occlusion.